GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syngene International Ltd (BOM:539268) » Definitions » Gross Margin %

Syngene International (BOM:539268) Gross Margin % : 77.88% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Syngene International Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Syngene International's Gross Profit for the three months ended in Mar. 2024 was ₹7,141 Mil. Syngene International's Revenue for the three months ended in Mar. 2024 was ₹9,169 Mil. Therefore, Syngene International's Gross Margin % for the quarter that ended in Mar. 2024 was 77.88%.


The historical rank and industry rank for Syngene International's Gross Margin % or its related term are showing as below:

BOM:539268' s Gross Margin % Range Over the Past 10 Years
Min: 69.03   Med: 72.01   Max: 74.8
Current: 73.34


During the past 13 years, the highest Gross Margin % of Syngene International was 74.80%. The lowest was 69.03%. And the median was 72.01%.

BOM:539268's Gross Margin % is ranked better than
66.67% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs BOM:539268: 73.34

Syngene International had a gross margin of 77.88% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Syngene International was 0.80% per year.


Syngene International Gross Margin % Historical Data

The historical data trend for Syngene International's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syngene International Gross Margin % Chart

Syngene International Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.37 74.80 70.12 73.06 73.34

Syngene International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.45 72.43 70.64 72.19 77.88

Competitive Comparison of Syngene International's Gross Margin %

For the Biotechnology subindustry, Syngene International's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syngene International's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syngene International's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Syngene International's Gross Margin % falls into.



Syngene International Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Syngene International's Gross Margin for the fiscal year that ended in Mar. 2024 is calculated as

Gross Margin % (A: Mar. 2024 )=Gross Profit (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=25584 / 34886
=(Revenue - Cost of Goods Sold) / Revenue
=(34886 - 9302) / 34886
=73.34 %

Syngene International's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=7141 / 9169
=(Revenue - Cost of Goods Sold) / Revenue
=(9169 - 2028) / 9169
=77.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Syngene International  (BOM:539268) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Syngene International had a gross margin of 77.88% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Syngene International Gross Margin % Related Terms

Thank you for viewing the detailed overview of Syngene International's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Syngene International (BOM:539268) Business Description

Traded in Other Exchanges
Address
Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.

Syngene International (BOM:539268) Headlines

No Headlines